TAR DNA-binding protein 43 (TDP-43) proteinopathy represents the hallmark neuropathological feature of most frontotemporal dementia (FTD) cases and nearly all amyotrophic lateral sclerosis (ALS) cases. The selective vulnerability of specific neuronal populations to TDP-43 pathology provides critical insights into disease mechanisms and potential therapeutic targets.
TDP-43 is a nuclear RNA/DNA-binding protein that regulates gene expression and RNA splicing. In disease, TDP-43 mislocalizes from the nucleus to the cytoplasm, forms insoluble aggregates, and results in loss of nuclear function. This proteinopathy affects specific neuronal populations in a pattern that defines the clinical phenotype [1].
| Property |
Value |
| Protein |
TARDBP (TDP-43) |
| Location |
Chromosome 1p36.22 |
| **Molecular weight |
43 kDa |
| Cases affected |
~95% FTD, ~97% ALS |
TDP-43 participates in multiple cellular processes:
- RNA metabolism: Alternative splicing, mRNA stability, transport
- Gene transcription: Transcriptional regulation
- DNA repair: Involvement in DNA damage response
- Stress granules: Transient stress response formation
- Nuclear export increased
- Cytoplasmic accumulation
- Formation of stress granules
- Hyperphosphorylation
- Ubiquitination
- C-terminal fragments
- Insoluble inclusions
- Nuclear TDP-43 depletion
- Altered RNA splicing
- Dysregulated gene expression
These neurons are highly vulnerable in ALS-FTD:
| Feature |
Details |
| Location |
Primary motor cortex (Betz cells, layer 5) |
| Axon |
Corticospinal tract |
| Vulnerability |
Very high in ALS |
| Pathology |
cytoplasmic inclusions, loss |
Betz Cells
- Largest pyramidal neurons in motor cortex
- Very high metabolic demand
- Long axonal projections
- Early and severe involvement in ALS
Corticospinal Projection Neurons
- Layer 5 pyramidal neurons
- Widespread cortical origins
- Degeneration in ALS and FTD
- Spinal motor neurons: Anterior horn cells
- Brainstem motor nuclei: Hypoglossal, ambiguus, facial
- Very high vulnerability: Severe loss in ALS
These neurons show early vulnerability in FTD:
- Behavioral variant FTD: Most affected
- Progressive aphasia: Variable involvement
- Synaptic dysfunction: Early marker
- Connections: Thalamus and other cortical areas
- Function: Integration and relay
- Pathology: Significant in FTD-MND
These specialized neurons are selectively vulnerable:
- Location: Layer 5 of anterior cingulate and frontoinsular cortex
- Function: Social cognition, empathy
- Vulnerability: Particularly affected in behavioral variant FTD
- Significance: May explain early social/emotional deficits
- CA1 pyramidal neurons: Moderate involvement
- Dentate gyrus granule cells: Less affected
- Subiculum: Variable involvement
- Semantic dementia: Severe temporal involvement
- Temporal horn dilation: Common finding
- Moderate vulnerability
- Contributes to memory dysfunction
- Interaction with cortical pathology
- Medium spiny neurons: Affected in FTD
- Interneurons: Variable involvement
- Contributes to movement abnormalities
| FTD Variant |
Primary Pathology Location |
Key Affected Neurons |
| bvFTD |
Frontal cortex, anterior cingulate |
VENs, Layer 5 pyramids |
| svPPA |
Anterior temporal lobe |
Temporal pyramids |
| nfvPPA |
Posterior frontal, insula |
Left inferior frontal |
| FTD-MND |
Motor cortex, motor neurons |
Upper + lower MN |
- Classic ALS: Motor cortex + spinal MN
- Progressive bulbar palsy: Brainstem MN
- Primary lateral sclerosis: Upper MN only
- Flail arm syndrome: Cervical motor neurons
| Gene |
Mutation |
Phenotype |
| TARDBP |
M337V, G298S |
ALS, FTD-ALS |
| GRN |
Null mutations |
FTD with TDP-43 |
| C9orf72 |
Repeat expansion |
ALS-FTD |
- TMEM106B: Risk factor for FTD
- APOE: Modifies progression
- UNC13A: ALS risk modifier
Microglia play a key role in TDP-43 pathology:
- Early activation: Precedes neuronal loss
- Chronic inflammation: Drives progression
- TREM2 involvement: Risk factor
- Therapeutic target: Anti-inflammatory approaches
- Reactive astrocytes: Surround affected neurons
- Loss of supportive function: Contributes to degeneration
- A1/A2 phenotypes: Disease-specific patterns
- Small molecule inhibitors
- Antisense oligonucleotides (ASOs)
- Autophagy enhancers
- Nuclear import enhancers
- ASOs targeting toxic fragments
- Anti-inflammatory agents
- Mitochondrial protectors
- Antiexcitotoxic approaches
| Symptom |
Treatment |
| Cognitive decline |
Cholinesterase inhibitors |
| Behavioral changes |
SSRIs, antipsychotics |
| Motor symptoms |
Riluzole, physical therapy |
| Speech/ swallowing |
Speech therapy, feeding support |
- CSF TDP-43: Elevated in disease
- Neurofilament light chain (NfL): Disease progression marker
- MRI: Pattern of atrophy
- PET: FDG-PAT metabolic patterns
- Age at onset: Earlier = faster progression
- C9orf72 status: Repeat expansion = more rapid
- Initial phenotype: ALS-FTD faster than FTD alone
- Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006
- Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011
- Burrell JR, Halliday GM, Kril JJ, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016
- Gao FB, Almeida S, Carmichael S. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J. 2021
- Proust-Lima C, Amieva H, Dartigues JF, et al. Sensitivity and specificity of cerebrospinal fluid biomarkers in the diagnosis of Alzheimer's disease. JAMA Neurol. 2015